Search

everythinglearnresearchcommunity

for

Search:↓

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Nilotinib can cause generalized keratosis pilaris.

The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

The combination of encorafenib and binimetinib caused few skin issues.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

Ruxolitinib can cause a delayed skin reaction on the nose.

Imatinib can cause hair loss due to lichen planopilaris.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Tofacitinib may help treat severe hair loss, but more research is needed.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Erlotinib can cause excessive eyelash growth.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

Stopping gefitinib improved scalp condition in a woman with lung cancer.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.